Accumulating evidence from epidemiological and human intervention studies indicates that the cardiovascular health benefits of diets rich in fruits and vegetables are (in part) related to their (poly)phenol content. Cranberries are rich in (poly)phenols compounds, in particular anthocyanins, but also phenolic acids. At present, a small number of randomized controlled trials investigating the effects of berry (poly)phenols on validated surrogate markers of cardiovascular disease risk has shown promising results. However, to date, very few human studies have specifically investigated the effects of cranberry (poly)phenols on cardiovascular function in healthy subjects. To our knowledge, no study has investigated the time and intake-dependent effect of cranberry consumption on vascular function in healthy subjects. This information is necessary for the planning of long-term studies aiming to assess the potential beneficial effects of cranberries, using optimal amounts at optimal time points. Therefore, this study aims to investigate the potential role of cranberry (poly)phenols in the modulation of vascular function by monitoring changes in vascular function together with the major (poly)phenol derivatives/metabolites in plasma and urine.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
10
Dietary Supplement: Cranberry beverage with 320 mg of (poly)phenols Acute intake of 500 mL (1x daily)
Dietary Supplement: Cranberry beverage with 640 mg of (poly)phenols Acute intake of 500 mL (1x daily)
Dietary Supplement: Cranberry beverage with 960 mg of (poly)phenols Acute intake of 500 mL (1x daily)
Dietary Supplement: Cranberry beverage with 1280 mg of (poly)phenols Acute intake of 500 mL (1x daily)
Dietary Supplement: Cranberry beverage with 1600 mg of (poly)phenols Acute intake of 500 mL (1x daily)
Cranberry deprived supplement Acute intake of 500 mL (1x daily)
Division of Cardiology, Pulmonary Disease and Vascular Medicine, University Hospital Duesseldorf
Düsseldorf, Germany
Endothelial function
measured by Flow mediated dilation at 1, 2, 4, 6 and 8 hours after intake
Time frame: Baseline, on week 1, 2, 3, 4 and 5 postconsumption
pulse wave velocity
measured by SphygmoCor at 0, 1, 2, 4, 6 and 8 hours after intake
Time frame: Baseline, on week 1, 2, 3, 4 and 5 postconsumption
Central blood pressure
measured by SphygmoCor at 0, 1.5, 4, 6 and 8 hours after intake
Time frame: Baseline, on week 1, 2, 3, 4 and 5 postconsumption
Peripheral blood pressure
measured by automatic sphygmomanometer at 0, 1, 2, 4, 6 and 8 hours after intake
Time frame: Baseline, on week 1, 2, 3, 4 and 5 postconsumption
Heart Rate
measured by SphygmoCor 0, 1, 2, 4, 6 and 8 hours after intake
Time frame: Baseline, on week 1, 2, 3, 4 and 5 postconsumption
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.